{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kong J"],"funding":["National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology","National Natural Science Foundation of China"],"pagination":["246-257"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8942255"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["Src homology 2 domain-containing protein tyrosine phosphatase (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the <i>Ptpn11</i> gene, which regulates cell growth, differentiation and apoptosis <i>via</i> modulating various signaling pathways, such as the RAS/ERK signaling pathway, and participates in the PD-1/PD-L1 pathway governing immune surveillance. It has been recognized as a breakthrough antitumor therapeutic target. Besides, numerous studies have shown that SHP2 plays an important role in the regulation of inflammatory diseases. However, inhibitors targeting the active site of SHP2 lack drug-likeness due to their low selectivity and poor bioavailability, thus none has advanced to clinical development. Recently, allosteric inhibitors that stabilize the inactive confo"],"journal":["RSC medicinal chemistry"],"pubmed_title":["Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors."],"pmcid":["PMC8942255"],"funding_grant_id":["81761128022","2018ZX09711002-006-004","21772214"],"pubmed_authors":["Kong J","Long YQ"],"additional_accession":[]},"is_claimable":false,"name":"Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.","description":"Src homology 2 domain-containing protein tyrosine phosphatase (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the <i>Ptpn11</i> gene, which regulates cell growth, differentiation and apoptosis <i>via</i> modulating various signaling pathways, such as the RAS/ERK signaling pathway, and participates in the PD-1/PD-L1 pathway governing immune surveillance. It has been recognized as a breakthrough antitumor therapeutic target. Besides, numerous studies have shown that SHP2 plays an important role in the regulation of inflammatory diseases. However, inhibitors targeting the active site of SHP2 lack drug-likeness due to their low selectivity and poor bioavailability, thus none has advanced to clinical development. Recently, allosteric inhibitors that stabilize the inactive confo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-19T20:50:27.213Z","creation":"2025-04-19T20:50:27.213Z"},"accession":"S-EPMC8942255","cross_references":{"pubmed":["35434626"],"doi":["10.1039/d1md00386k"]}}